Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives.

Ademi Z, Sutherland CS, Van Stiphout J, Michaud J, Tanackovic G, Schwenkglenks M.

J Thromb Thrombolysis. 2017 Nov;44(4):494-506. doi: 10.1007/s11239-017-1554-5. Review.


Risk prediction of developing venous thrombosis in combined oral contraceptive users.

McDaid A, Logette E, Buchillier V, Muriset M, Suchon P, Pache TD, Tanackovic G, Kutalik Z, Michaud J.

PLoS One. 2017 Jul 27;12(7):e0182041. doi: 10.1371/journal.pone.0182041. eCollection 2017.


About Pill Protect®.

Michaud J, Tanackovic G.

Swiss Med Wkly. 2016 Dec 5;146:w14392. doi: 10.4414/smw.2016.14392. eCollection 2016. No abstract available.


About Pill Protect®.

Michaud J, Tanackovic G.

Swiss Med Wkly. 2016 Dec 5;146:w14392. doi: 10.4414/smw.2016.14392. eCollection 2016 Dec 5. No abstract available.


Carriers of the fragile X mental retardation 1 (FMR1) premutation allele present with increased levels of cytokine IL-10.

Marek D, Papin S, Ellefsen K, Niederhauser J, Isidor N, Ransijn A, Poupon L, Spertini F, Pantaleo G, Bergmann S, Beckmann JS, Jacquemont S, Tanackovic G.

J Neuroinflammation. 2012 Oct 13;9:238. doi: 10.1186/1742-2094-9-238.


Recurrent dominant mutations affecting two adjacent residues in the motor domain of the monomeric kinesin KIF22 result in skeletal dysplasia and joint laxity.

Boyden ED, Campos-Xavier AB, Kalamajski S, Cameron TL, Suarez P, Tanackovic G, Andria G, Ballhausen D, Briggs MD, Hartley C, Cohn DH, Davidson HR, Hall C, Ikegawa S, Jouk PS, König R, Megarbané A, Nishimura G, Lachman RS, Mortier G, Rimoin DL, Rogers RC, Rossi M, Sawada H, Scott R, Unger S, Valadares ER, Bateman JF, Warman ML, Superti-Furga A, Bonafé L.

Am J Hum Genet. 2011 Dec 9;89(6):767-72. doi: 10.1016/j.ajhg.2011.10.016. Erratum in: Am J Hum Genet. 2012 Jan 13;90(1):170. Tanackovich, Goranka [corrected to Tanackovic, Goranka].


A missense mutation in PRPF6 causes impairment of pre-mRNA splicing and autosomal-dominant retinitis pigmentosa.

Tanackovic G, Ransijn A, Ayuso C, Harper S, Berson EL, Rivolta C.

Am J Hum Genet. 2011 May 13;88(5):643-9. doi: 10.1016/j.ajhg.2011.04.008. Epub 2011 May 5.


PRPF mutations are associated with generalized defects in spliceosome formation and pre-mRNA splicing in patients with retinitis pigmentosa.

Tanackovic G, Ransijn A, Thibault P, Abou Elela S, Klinck R, Berson EL, Chabot B, Rivolta C.

Hum Mol Genet. 2011 Jun 1;20(11):2116-30. doi: 10.1093/hmg/ddr094. Epub 2011 Mar 5.


Analysis of in situ pre-mRNA targets of human splicing factor SF1 reveals a function in alternative splicing.

Corioni M, Antih N, Tanackovic G, Zavolan M, Krämer A.

Nucleic Acids Res. 2011 Mar;39(5):1868-79. doi: 10.1093/nar/gkq1042. Epub 2010 Nov 9.


PRPF31 alternative splicing and expression in human retina.

Tanackovic G, Rivolta C.

Ophthalmic Genet. 2009 Jun;30(2):76-83. doi: 10.1080/13816810902744621.


Analysis of cystic fibrosis gene mutations and associated haplotypes in the Croatian population.

Knezević J, Tanacković G, Matijević T, Barisić I, Pavelić J.

Genet Test. 2007 Summer;11(2):133-8.


Structure-function analysis of the U2 snRNP-associated splicing factor SF3a.

Krämer A, Ferfoglia F, Huang CJ, Mulhaupt F, Nesic D, Tanackovic G.

Biochem Soc Trans. 2005 Jun;33(Pt 3):439-42. Review.


Human splicing factor SF3a, but not SF1, is essential for pre-mRNA splicing in vivo.

Tanackovic G, Krämer A.

Mol Biol Cell. 2005 Mar;16(3):1366-77. Epub 2005 Jan 12.


A role for Cajal bodies in the final steps of U2 snRNP biogenesis.

Nesic D, Tanackovic G, Krämer A.

J Cell Sci. 2004 Sep 1;117(Pt 19):4423-33. Epub 2004 Aug 17.


The incidence of cystic fibrosis (CF) mutations among patients from Croatia.

Tanacković G, Barisić I, Gjergja-Matejić R, Hećimović S, Pavelić J.

Clin Genet. 2000 Oct;58(4):333-5. No abstract available.


Supplemental Content

Loading ...
Support Center